For research use only. Not for therapeutic Use.
Bapotulimab（Cat No.:I042164）is an investigational monoclonal antibody that targets the immune checkpoint receptor TIGIT (T-cell immunoreceptor with Ig and ITIM domains), which plays a role in suppressing immune responses. TIGIT is expressed on T-cells and NK cells and helps tumors evade immune detection. By inhibiting TIGIT, bapotulimab aims to restore T-cell activation, enhance anti-tumor immunity, and improve the body’s ability to fight cancer. It is being studied in clinical trials for its potential to treat various cancers, including solid tumors and hematologic malignancies, with the goal of improving patient outcomes through immune modulation.
| Catalog Number | I042164 |
| CAS Number | 2359413-58-2 |
| Purity | ≥95% |
